← Back to Search

Other

Urolithin A Supplementation for Obesity

N/A
Recruiting
Led By Andriy Yabluchanskiy, MD, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 40-64 years old, inclusive
Obesity [BMI ≥30 kg/m2]
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 0) and endpoint (day 28)
Awards & highlights

Study Summary

This trial tests if taking a dietary supplement can improve blood flow in middle-aged adults with obesity. Participants will take the supplement and have their blood vessels, blood, and answers to questionnaires checked.

Who is the study for?
This trial is for middle-aged adults (40-64 years old) with obesity, defined as having a BMI of 30 or higher. Participants must be able to understand and consent in English. It's not open to those with cognitive impairments, swallowing issues, recent heart problems, severe mental health conditions like depression or anxiety, significant GI diseases, allergies to the supplement ingredients, active cancer treatment, diabetes history or neurodegenerative disorders.Check my eligibility
What is being tested?
The study tests if Urolithin A supplementation can improve blood flow in large and small vessels among obese middle-aged adults. Over four weeks participants will take either this dietary supplement or a placebo daily. Their vascular health will be assessed through two visits involving vessel checks and questionnaires.See study design
What are the potential side effects?
Potential side effects are not detailed here but could include reactions related to individual intolerance to the components of Urolithin A or the placebo substance used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 64 years old.
Select...
My BMI is 30 or higher.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 0) and endpoint (day 28)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 0) and endpoint (day 28) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in arterial function and local stiffness
Secondary outcome measures
Change in blood flow on the surface of the hand
Change in homeostatic cerebral blood flow
Change in plasma biomarkers of NO homeostasis
+1 more
Other outcome measures
Body fat percentage
Body weight
Waist circumference

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: InterventionExperimental Treatment1 Intervention
Group II: ControlPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Amazentis SAIndustry Sponsor
16 Previous Clinical Trials
1,095 Total Patients Enrolled
University of OklahomaLead Sponsor
455 Previous Clinical Trials
95,869 Total Patients Enrolled
Andriy Yabluchanskiy, MD, PhDPrincipal InvestigatorUniversity of Oklahoma Health Science Center
3 Previous Clinical Trials
72 Total Patients Enrolled

Media Library

Placebo (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05921266 — N/A
Cognitive Impairment Research Study Groups: Control, Intervention
Cognitive Impairment Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05921266 — N/A
Placebo (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05921266 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment have an open call for participants?

"Currently, clinicaltrials.gov data suggests that this medical experiment is not actively recruiting patients. This trial was first posted on July 1st 2023 and its last update occurred on June 25th 2023. Though this specific study has ceased recruitment for the moment, there are still 1925 other trials searching for willing participants right now."

Answered by AI

Is it possible for me to be a part of this medical experiment?

"To be part of the trial, potential participants should have a BMI that classifies them as obese and must be aged between 40 to 64. The research team is in search for 54 individuals that meet this criteria."

Answered by AI

Are participants of this research study limited to adults?

"This clinical trial is only open to applicants between the age of 40 and 64, as specified in their inclusion criteria. Conversely, there are 230 active trials for minors under 18 years old and 1523 studies available for elderly people over 65."

Answered by AI

Who else is applying?

What site did they apply to?
Translational GeroScience Laboratory - O'Donoghue Reserach Building
Translational GeroScience Laboratory - O'Donoghue Research Building
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

I've tried various methods for weight loss that either didn't work, or did work but the weight came right back on after stopping treatment.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Urolithin A Supplementation in Middle-aged Adults With Obesity
2023. "Urolithin A Supplementation in Middle-aged Adults With Obesity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05921266.
~25 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top